Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
| The following article features coverage from the American Society of Hematology 2019 Annual Meeting. Click here to read more of Oncology Nurse Advisor‘s conference coverage. |
In this ongoing trial, patients (N=74) with MF and anemia receive the erythroid maturation agent luspatercept at 21-day intervals. Patients were assigned to cohorts based on red blood cell transfusion-dependent status at baseline and whether they had been receiving treatment with ruxolitinib at the start of the study.
Data from an interim analysis of a phase 2 trial suggest that luspatercept shows efficacy in the treatment of anemia associated with myelofibrosis (MF), according to study results presented at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition, held in Orlando, Florida.
In cohorts 1 and 2, patients had not received ruxolitinib, but cohort 1 patients (n=20) were nontransfusion dependent (NTD), and cohort 2 patients (n=21) were transfusion dependent (TD). In cohorts 3A and 3B, patients had received ruxolitinib, but cohort 3A patients (n=14) had NTD status, whereas cohort 3B patients (n=19) had TD status.
In intent-to-treat analysis, the percentages of NTD patients who showed a consistent hemoglobin improvement of 1.5 g/dL or more above baseline at each evaluation for 12 consecutive weeks were 10% in cohort 1 and 21% in cohort 3A. Patients who were initially TD demonstrated transfusion independence for 12 or more consecutive weeks at rates of 10% in cohort 2 and 32% in cohort 3B.
A mean hemoglobin increase of at least 1.5 g/dL was reported for 15% of cohort 1 patients and 57% of cohort 3A patients. A reduction in transfusion burden of 50% or more was reported for 38% of cohort 2 patients and 53% of cohort 3B patients.
Grade 3 to 4 treatment-related adverse events were reported in 5% of patients, and there were no treatment-related deaths.
The study authors indicated that in this study luspatercept has so far demonstrated activity that appears clinically significant and with a low level of grade 3 to 4 adverse events.
Disclosure: Multiple authors declared affiliations with industry. Please refer to the original abstract for a full list of disclosures.
Reference
Gerds AT, Vannucchi AM, Passamonti F, et al. A phase 2 study of luspatercept in patients with myelofibrosis-associated anemia. Oral presentation at: 61st ASH Annual Meeting & Exposition; December 7-10, 2019; Orlando, FL. Abstract 557.
